Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial

Follow-up analyses performed after median follow-up of 48.8 months found 3-year event-free survival was similar for the anthracycline group (92.7%; 95% CI 89.3%-96.2%) and the non-anthracycline group (93.6%; 90.4%-96.9%), as were 3-year overall survival estimates (97.7% v 98.2%).

Source:

JAMA Oncology